Neurocrine Biosciences
NBIX
#1395
Rank
C$17.78 B
Marketcap
$175.66
Share price
0.52%
Change (1 day)
14.35%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - P/B ratio

P/B ratio as of November 2024 : 4.65

According to Neurocrine Biosciences 's latest financial reports the company has a price-to-book ratio of 5.64221.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Neurocrine Biosciences - P/B ratio (from 2001 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-31N/A-100%
2023-12-315.80-13.73%
2022-12-316.7214.33%
2021-12-315.88-26.05%
2020-12-317.95-48.94%
2019-12-3115.615.47%
2018-12-3113.5-26.91%
2017-12-3118.572.81%
2016-12-3110.7-7.13%
2015-12-3111.540.46%
2014-12-318.1956.68%
2013-12-315.2262.26%
2012-12-313.22-58.81%
2011-12-317.82-63.93%
2010-12-3121.7-28.38%
2009-12-3130.3801%
2008-12-313.36129.43%
2007-12-311.4616.64%
2006-12-311.26-78.98%
2005-12-315.9730.56%
2004-12-314.57-7.13%
2003-12-314.92-21.13%
2002-12-316.24

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
4.06-12.70%๐Ÿ‡บ๐Ÿ‡ธ USA
1.52-67.40%๐Ÿ‡ฌ๐Ÿ‡ง UK
-169-3,724.99%๐Ÿ‡บ๐Ÿ‡ธ USA
49.6 966.30%๐Ÿ‡บ๐Ÿ‡ธ USA
51.6 1,008.04%๐Ÿ‡บ๐Ÿ‡ธ USA
1.56-66.40%๐Ÿ‡บ๐Ÿ‡ธ USA
2.49-46.53%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0229-100.49%๐Ÿ‡บ๐Ÿ‡ธ USA